1
|
Yan F, Mutembei B, Valerio T, Gunay G, Ha JH, Zhang Q, Wang C, Selvaraj Mercyshalinie ER, Alhajeri ZA, Zhang F, Dockery LE, Li X, Liu R, Dhanasekaran DN, Acar H, Chen WR, Tang Q. Optical coherence tomography for multicellular tumor spheroid category recognition and drug screening classification via multi-spatial-superficial-parameter and machine learning. Biomed Opt Express 2024; 15:2014-2047. [PMID: 38633082 PMCID: PMC11019711 DOI: 10.1364/boe.514079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 02/12/2024] [Accepted: 02/20/2024] [Indexed: 04/19/2024]
Abstract
Optical coherence tomography (OCT) is an ideal imaging technique for noninvasive and longitudinal monitoring of multicellular tumor spheroids (MCTS). However, the internal structure features within MCTS from OCT images are still not fully utilized. In this study, we developed cross-statistical, cross-screening, and composite-hyperparameter feature processing methods in conjunction with 12 machine learning models to assess changes within the MCTS internal structure. Our results indicated that the effective features combined with supervised learning models successfully classify OVCAR-8 MCTS culturing with 5,000 and 50,000 cell numbers, MCTS with pancreatic tumor cells (Panc02-H7) culturing with the ratio of 0%, 33%, 50%, and 67% of fibroblasts, and OVCAR-4 MCTS treated by 2-methoxyestradiol, AZD1208, and R-ketorolac with concentrations of 1, 10, and 25 µM. This approach holds promise for obtaining multi-dimensional physiological and functional evaluations for using OCT and MCTS in anticancer studies.
Collapse
Affiliation(s)
- Feng Yan
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Bornface Mutembei
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Trisha Valerio
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Gokhan Gunay
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Ji-Hee Ha
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Qinghao Zhang
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Chen Wang
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | | | - Zaid A. Alhajeri
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Fan Zhang
- Department of Radiology, School of Medicine, University of Washington, Seattle, WA 98195, USA
| | - Lauren E. Dockery
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Xinwei Li
- Department of Electrical and Electronic Engineering, University of Nottingham, Nottingham NG7 2RD, United Kingdom
| | - Ronghao Liu
- School of Computer Science and Technology, Shandong Jianzhu University, Jinan 250100, China
| | - Danny N. Dhanasekaran
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Institute for Biomedical Engineering, Science, and Technology (IBEST), University of Oklahoma Norman, OK 73019, USA
| | - Wei R. Chen
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Institute for Biomedical Engineering, Science, and Technology (IBEST), University of Oklahoma Norman, OK 73019, USA
| | - Qinggong Tang
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Institute for Biomedical Engineering, Science, and Technology (IBEST), University of Oklahoma Norman, OK 73019, USA
| |
Collapse
|
2
|
Ürün M, Bora ES, Acar H, Erbaş O. Evaluation of the healing and protective properties of adipose-derived mesenchymal stem cells from cisplatin-induced liver and kidney damage. Eur Rev Med Pharmacol Sci 2024; 28:1327-1339. [PMID: 38436166 DOI: 10.26355/eurrev_202402_35454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
OBJECTIVE The occurrence of nephrotoxicity and hepatotoxicity as a result of cisplatin administration is a major concern in clinical practice. This study examined the potential protective effects of administering mesenchymal stem cells (MSCs) on the renal and hepatic damage caused by cisplatin. Moreover, the study investigated the potential protective effects of administering Adipose-Derived Mesenchymal Stem Cells (ADMSC) to counteract the harmful effects of cisplatin-induced kidney and liver damage. MATERIALS AND METHODS Male Sprague-Dawley rats were divided into three groups: normal control, cisplatin + saline, and cisplatin + ADMSC. Cisplatin was administered to induce toxicity, and ADMSC was administered intravenously as a potential therapeutic intervention. Biochemical parameters and histopathological changes were assessed in the kidney and liver tissues. Statistical analyses were performed using a one-way ANOVA. RESULTS Cisplatin increased malondialdehyde (MDA), tumor necrosis factor alfa (TNF-alfa), IL-6, alanine transaminase (ALT), creatinine, Galectin-3, Tissue growth factor beta 1 (TGF-beta 1), compared to the normal control group. Cisplatin-MSC reduced these levels. Histopathology showed that cisplatin caused kidney tubular epithelial necrosis, luminal necrotic debris, tubular dilatation, interstitial inflammation, liver sinusoidal and central vein dilatation, congestion, necrosis, and cytoplasmic vacuolization. ADMSC administration significantly reduced histopathological changes. CONCLUSIONS These findings highlight the potential therapeutic benefits of mesenchymal stem cell (MSC) administration in mitigating cisplatin-induced nephrotoxicity and hepatotoxicity. MSC treatment demonstrated protective effects by reducing oxidative stress, inflammatory markers, and histopathological alterations. Further investigations are warranted to elucidate the precise mechanisms underlying these protective effects and evaluate their clinical implications for managing cisplatin-induced organ damage.
Collapse
Affiliation(s)
- M Ürün
- Oncology Department, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey.
| | | | | | | |
Collapse
|
3
|
Çınaroğlu O, Bora E, Acar H, Arıkan C, Küçük M, Kırık S. Is near-infrared spectroscopy a promising predictor for early intracranial hemorrhage diagnosis in the Emergency Department? Braz J Med Biol Res 2024; 57:e13155. [PMID: 38265345 PMCID: PMC10802232 DOI: 10.1590/1414-431x2023e13155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Accepted: 12/04/2023] [Indexed: 01/25/2024] Open
Abstract
Intracranial hemorrhage (ICH) is a serious medical condition that can lead to significant morbidity and mortality if not diagnosed and treated promptly. Early detection and treatment are essential for improving the outcome in patients with ICH. Near-infrared spectroscopy (NIRS) is a non-invasive imaging technique that has been used to detect changes in brain tissue oxygenation and blood flow in various conditions. The aim of this study was to investigate the predictive potential of NIRS for early diagnosis of ICH in patients presenting to the Emergency Department (ED) triage with headache. A total of 378 patients were included in the study. According to the final diagnosis of the patients, 4 groups were formed: migraine, tension-cluster headache, intracranial hemorrhage and intracranial mass, and control group. Cerebral NIRS values "rSO2" were measured at the first professional medical contact with the patient. The right and left rSO2 (RrSO2, LrSO2) were significantly lower and the rSO2 difference was significantly higher in the intracranial hemorrhage group compared to all other patient groups (P<0.001). The cut-off values determined in the receiver operating characteristics (ROC) analysis were RrSO2 ≤67, LrSO2 ≤67, and ΔrSO2 ≥9. This study found that a difference of more than 9 in cerebral right-left NIRS values can be a non-invasive, easy-to-administer, rapid, and reliable diagnostic test for early detection of intracranial bleeding. NIRS holds promise as an objective method in ED triage for patients with intracranial hemorrhage. However, further research is needed to fully understand the potential benefits and limitations of this method.
Collapse
Affiliation(s)
- O.S. Çınaroğlu
- Department of Emergency Medicine, Izmir Katip Celebi University, Izmir, Turkey
| | - E.S. Bora
- Department of Emergency Medicine, Izmir Ataturk Training and Research Hospital, Izmir, Turkey
| | - H. Acar
- Department of Emergency Medicine, Izmir Katip Celebi University, Izmir, Turkey
| | - C. Arıkan
- Department of Emergency Medicine, Izmir Ataturk Training and Research Hospital, Izmir, Turkey
| | - M. Küçük
- Department of Emergency Medicine, Buca Seyfi Demirsoy Training and Research Hospital, Izmir, Turkey
| | - S. Kırık
- Department of Emergency Medicine, Izmir Katip Celebi University, Izmir, Turkey
| |
Collapse
|
4
|
Kernder A, Rohde M, Acar H, Düsing C, Fischer-Betz R, Haase I, Mucke J, Sander O, Richter JG, Filla T, Schneider M, Chehab G. Patient-reported outcomes in large vessel vasculitis: insights from a retrospective analysis of disease activity and associated factors. J Patient Rep Outcomes 2024; 8:4. [PMID: 38285076 PMCID: PMC10825095 DOI: 10.1186/s41687-023-00681-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 12/18/2023] [Indexed: 01/30/2024] Open
Abstract
BACKGROUND Patient-reported outcomes (PROs) play a crucial role in assessing rheumatic diseases, offering insights into disease evaluation and treatment efficacy. This study focuses on PRO assessment in large vessel vasculitides, including Takayasu Arteritis and Giant Cell Arteritis (GCA). METHODS We retrospectively analyzed routine data from patients treated at our rheumatology clinic over a 10-year span. Patient and physician-rated global disease activity scale (G-DAS) scores, measured on a numeric rating scale (0-10 points), were collected at each visit. Clinical variables like age, sex, body mass index (BMI), disease duration, lab values, pain perception, and questionnaire responses were recorded. Linear regression and generalized additive linear regression (GAM analysis) examined associations between PROs and these factors. RESULTS The study included 138 patients, primarily diagnosed with GCA (94.4%). Mean follow-up was 2.5 years (0-7.7). Patient and physician G-DAS exhibited a moderate correlation (Pearson R 0.19, CI 0.14-0.24, p < 0.001). Higher patient G-DAS correlated with younger age (CI -3.4 - -1.5, p < 0.001), increased pain (CI 3.5-4, p < 0.001), functional limitations (HAQ, CI 0.5-0.6, p < 0.001), reduced physical (CI 2.3-2.7, p ≤ 0.001) and psychological well-being (CI 2.1-2.5, p < 0.001), and higher BMI (CI 1.3-2.4, p < 0.001). Physician G-DAS correlated with Birmingham Vasculitis Activity Score (V3.0; R 0.42, p 0.046) and were significantly linked to serum CRP elevations (β = 0.04, CI 0.0-0.08, p 0.028). CONCLUSIONS These findings underscore the need to integrate PRO measures into vasculitis disease management strategies, enhancing the understanding of disease activity from the patient's perspective.
Collapse
Affiliation(s)
- A Kernder
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany.
| | - M Rohde
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - H Acar
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - C Düsing
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - R Fischer-Betz
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - I Haase
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - J Mucke
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - O Sander
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - J G Richter
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - T Filla
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - M Schneider
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - G Chehab
- Department of Rheumatology, Medical Faculty of Heinrich, University Hospital Düsseldorf, Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| |
Collapse
|
5
|
Gunay G, Maier KN, Hamsici S, Carvalho F, Timog TA, Acar H. Peptide aggregation-induced immunogenic cell death in a breast cancer spheroid model. bioRxiv 2023:2023.10.31.565012. [PMID: 37961293 PMCID: PMC10635027 DOI: 10.1101/2023.10.31.565012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
Abstract
Utilizing multicellular aggregates (spheroids) for in vitro cancer research offers a physiologically relevant model that closely mirrors the intricate tumor microenvironment, capturing properties of solid tumors such as cell interactions and drug resistance. In this research, we investigated the Peptide-Aggregation Induced Immunogenic Response (PAIIR), an innovative method employing engineered peptides we designed specifically to induce immunogenic cell death (ICD). We contrasted PAIIR-induced ICD with standard ICD and non-ICD inducer chemotherapeutics within the context of three-dimensional breast cancer tumor spheroids. Our findings reveal that PAIIR outperforms traditional chemotherapeutics in its efficacy to stimulate ICD. This is marked by the release of key damage-associated molecular patterns (DAMPs), which bolster the phagocytic clearance of dying cancer cells by dendritic cells (DCs) and, in turn, activate powerful anti-tumor immune responses. Additionally, we observed that PAIIR results in elevated dendritic cell activation and increased antitumor cytokine presence. This study not only showcases the utility of tumor spheroids for efficient high-throughput screening but also emphasizes PAIIR's potential as a formidable immunotherapeutic strategy against breast cancer, setting the stage for deeper exploration and potential clinical implementation.
Collapse
|
6
|
Pineda-Castillo SA, Acar H, Detamore MS, Holzapfel GA, Lee CH. Modulation of Smooth Muscle Cell Phenotype for Translation of Tissue-Engineered Vascular Grafts. Tissue Eng Part B Rev 2023; 29:574-588. [PMID: 37166394 PMCID: PMC10618830 DOI: 10.1089/ten.teb.2023.0006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 04/25/2023] [Indexed: 05/12/2023]
Abstract
Translation of small-diameter tissue-engineered vascular grafts (TEVGs) for the treatment of coronary artery disease (CAD) remains an unfulfilled promise. This is largely due to the limited integration of TEVGs into the native vascular wall-a process hampered by the insufficient smooth muscle cell (SMC) infiltration and extracellular matrix deposition, and low vasoactivity. These processes can be promoted through the judicious modulation of the SMC toward a synthetic phenotype to promote remodeling and vascular integration; however, the expression of synthetic markers is often accompanied by a decrease in the expression of contractile proteins. Therefore, techniques that can precisely modulate the SMC phenotypical behavior could have the potential to advance the translation of TEVGs. In this review, we describe the phenotypic diversity of SMCs and the different environmental cues that allow the modulation of SMC gene expression. Furthermore, we describe the emerging biomaterial approaches to modulate the SMC phenotype in TEVG design and discuss the limitations of current techniques. In addition, we found that current studies in tissue engineering limit the analysis of the SMC phenotype to a few markers, which are often the characteristic of early differentiation only. This limited scope has reduced the potential of tissue engineering to modulate the SMC toward specific behaviors and applications. Therefore, we recommend using the techniques presented in this review, in addition to modern single-cell proteomics analysis techniques to comprehensively characterize the phenotypic modulation of SMCs. Expanding the holistic potential of SMC modulation presents a great opportunity to advance the translation of living conduits for CAD therapeutics.
Collapse
Affiliation(s)
- Sergio A. Pineda-Castillo
- Biomechanics and Biomaterials Design Laboratory, School of Aerospace and Mechanical Engineering, The University of Oklahoma, Norman, Oklahoma, USA
- Stephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma, USA
- Institute for Biomedical Engineering, Science and Technology, The University of Oklahoma, Norman, Oklahoma, USA
| | - Michael S. Detamore
- Stephenson School of Biomedical Engineering, The University of Oklahoma, Norman, Oklahoma, USA
- Institute for Biomedical Engineering, Science and Technology, The University of Oklahoma, Norman, Oklahoma, USA
| | - Gerhard A. Holzapfel
- Institute of Biomechanics, Graz University of Technology, Graz, Austria
- Department of Structural Engineering, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
| | - Chung-Hao Lee
- Biomechanics and Biomaterials Design Laboratory, School of Aerospace and Mechanical Engineering, The University of Oklahoma, Norman, Oklahoma, USA
- Institute for Biomedical Engineering, Science and Technology, The University of Oklahoma, Norman, Oklahoma, USA
| |
Collapse
|
7
|
Hamsici S, Gunay G, Acar H. Controllable membrane damage by tunable peptide aggregation with albumin. AIChE J 2022; 68:e17893. [PMID: 36816052 PMCID: PMC9937546 DOI: 10.1002/aic.17893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Aggregation of otherwise soluble proteins into amyloid structures is a hallmark of many disorders, such as Alzheimer's and Parkinson's disease. There is an increasing evidence that the small aggregations, instead of ordered fibrillar aggregates, are the main structures causing toxicity. However, the studies on the small aggregation phase are limited due to the variety of structures and the complexity of the physiological environment. Here, we showed an engineered co-assembling oppositely charged amyloid-like peptide pair ([II]) as a simple tool to establish methodologies to study the mechanism and kinetics of aggregation and relate its aggregation to toxicity. The toxicity mechanism of [II] is through cell membrane damage and stress, shown with YAP and eIF2α, as in the amyloid protein-initiated diseases. Albumin is demonstrated as an extrinsic and physiologically relevant molecule in controlling the aggregation lag time and toxicity of [II]. This study represents a molecular engineering strategy to create simplistic molecular tools for establishing methodologies to study the aggregation process and kinetics of amyloid-like proteins in various conditions. Understanding the nature of protein aggregation kinetics and linking them to their biological functions through engineered peptides paves the way for future designs and drug development applications.
Collapse
Affiliation(s)
- Seren Hamsici
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA
| | - Gokhan Gunay
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma, USA,Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
| |
Collapse
|
8
|
Gunay G, Hamsici S, Lang GA, Lang ML, Kovats S, Acar H. Peptide Aggregation Induced Immunogenic Rupture (PAIIR). Adv Sci (Weinh) 2022; 9:e2105868. [PMID: 35599386 PMCID: PMC9313945 DOI: 10.1002/advs.202105868] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 04/06/2022] [Indexed: 05/11/2023]
Abstract
Immunogenic cell death (ICD) arises when cells are under stress, and their membranes are damaged. They release damage-associated molecular patterns (DAMPs) that stimulate and drive the type and magnitude of the immune response. In the presence of an antigen, DAMPs ride the longevity and efficacy of antigen-specific immunity. Yet, no tool can induce the controlled ICD with predictable results. A peptide-based tool, [II], is designed that aggregates in the cell and causes cell membrane damage, generates ICD and DAMPs release on various cell types, and hence can act as an adjuvant. An influenza vaccine is prepared by combining [II] with influenza hemagglutinin (HA) subunit antigens. The results show that [II] induced significantly higher HA-specific immunoglobulin G1 (IgG1) and IgG2a antibodies than HA-only immunized mice, while the peptide itself did not elicit antibodies. This paper demonstrates the first peptide-aggregation induced immunogenic rupture (PAIIR) approach as a vaccine adjuvant. PAIIR is a promising adjuvant with a high potential to promote universal protection upon influenza HA vaccination.
Collapse
Affiliation(s)
- Gokhan Gunay
- Stephenson School of Biomedical EngineeringUniversity of OklahomaNormanOK73069USA
| | - Seren Hamsici
- Stephenson School of Biomedical EngineeringUniversity of OklahomaNormanOK73069USA
| | - Gillian A. Lang
- Department of Microbiology and ImmunologyUniversity of Oklahoma Health Sciences CenterOklahoma CityOK73104USA
| | - Mark L. Lang
- Department of Microbiology and ImmunologyUniversity of Oklahoma Health Sciences CenterOklahoma CityOK73104USA
| | - Susan Kovats
- Department of Microbiology and ImmunologyUniversity of Oklahoma Health Sciences CenterOklahoma CityOK73104USA
- Arthritis & Clinical Immunology ProgramOklahoma Medical Research FoundationOklahoma CityOK73104USA
| | - Handan Acar
- Stephenson School of Biomedical EngineeringUniversity of OklahomaNormanOK73069USA
- Stephenson Cancer CenterUniversity of Oklahoma Health Sciences CenterOklahoma CityOK73104USA
| |
Collapse
|
9
|
Kernder A, Rohde M, Acar H, Sander O, Richter J, Fischer-Betz R, Schneider M, Chehab G. POS1488-HPR DETERMINANTS OF PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN LARGE VESSEL VASCULITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundFactors influencing disease activity assessment by patients and physicians are unknown, but are highly relevant in the context of PROs development.ObjectivesTo compare the patients’ and physicians’ global assessment of disease activity in large vessel vasculitis and investigate factors influencing the assessment of disease activity.MethodsBetween 2010 and 2020, patients with large vessel vasculitis and their routine caring physicians assessed a global disease activity score (numerical rating scale 0 – 10) in our outpatient clinic. We compared these global scores of disease activity. In a multiple linear regression analysis we examined the influence of potential demographical and clinical factors on the disease activity assessment.Results138 Patients with 866 assessments were available for analysis. At timepoint of assessment they had a mean age of 76 (± 9) years and a mean disease duration of 5 years (± 5). The median global score of patient-reported disease activity was 3 points, the median physicians’ disease activity assessment was 2 points.In 28,2% (n=244) there was a deviation of more than 2 points between the patients’ and physicians’ assessment of disease activity. Only 5 times the physicians, but 232 times the patients rated their disease activity higher than 5 points.In this group the patient-reported disease activity was associated with the patients age (β 0.025), the patients BMI (β 0.071) and the extent of pain (β 0.19), p<0.05. The disease duration, CRP level and the psychological well-being of the patient showed no association.ConclusionIn our cohort, physicians and patients showed greater divergence in disease activity assessment with higher disease activity. Age, BMI and the extent of pain were associated with higher disease activity ratings by the patients. This results are relevant for the development and interpretation of PROs for activity assessment in large vessel vasculitides.Disclosure of InterestsAnna Kernder: None declared, Marius Rohde: None declared, Hasan Acar: None declared, Oliver Sander Speakers bureau: SOBI Pharma, EUSA Pharma, AbbVie Pharma, Consultant of: SOBI Pharma, EUSA Pharma, Boehringer Pharma, Jutta Richter: None declared, Rebecca Fischer-Betz: None declared, Matthias Schneider Speakers bureau: Astra-Zeneca; Biogen; BMS; Celgene; Chugai; GSK; Janssen-Cilag; Lilly; Pfizer; UCB, Paid instructor for: Lilly, Consultant of: Abbvie; Astra-Zeneca; Boehringer-Ingelheim; GSK; Lilly; Novartis; Pfizer; Protagen; Roche; Sanofi-Aventis; UCB, Grant/research support from: Abbvie; Astra-Zeneca; GSK; UCB, Gamal Chehab: None declared
Collapse
|
10
|
Abstract
Discovery of peptide domains with unique intermolecular interactions is essential for engineering peptide-based materials. Rather than attempting a brute-force approach, we instead identify a previously unexplored strategy for discovery and study of intermolecular interactions: “co-assembly of oppositely charged peptide” (CoOP), a framework that “encourages” peptide assembly by mixing two oppositely charged hexapeptides. We used an integrated computational and experimental approach, probed the free energy of association and probability of amino acid contacts during co-assembly with atomic-resolution simulations, and correlated them to the physical properties of the aggregates. We introduce CoOP with three examples: dialanine, ditryptophan, and diisoleucine. Our results indicated that the opposite charges initiate the assembly, and the subsequent stability is enhanced by the presence of an undisturbed hydrophobic core. CoOP represents a unique, simple, and elegant framework that can be used to identify the structure-property relationships of self-assembling peptide-based materials.
Collapse
Affiliation(s)
- Seren Hamsici
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73069 USA
| | - Andrew D. White
- Department of Chemical Engineering, University of Rochester, Rochester, NY 14627, USA
- Corresponding author. (A.D.W.); (H.A.)
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73069 USA
- Corresponding author. (A.D.W.); (H.A.)
| |
Collapse
|
11
|
Ajeeb B, Acar H, Detamore MS. Chondroinductive Peptides for Cartilage Regeneration. Tissue Eng Part B Rev 2021; 28:745-765. [PMID: 34375146 DOI: 10.1089/ten.teb.2021.0125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Inducing and maintaining a hyaline cartilage phenotype is the greatest challenge for cartilage regeneration. Synthetic chondroinductive biomaterials might be the answer to the unmet clinical need for a safe, stable, and cost-effective material capable of inducing true hyaline cartilage formation. The past decade witnessed an emergence of peptides to achieve chondrogenesis, as peptides have the advantages of versatility, high target specificity, minimized toxicity and immunogenicity, and ease of synthesis. Here, we review peptides as the basis for creating promising synthetic chondroinductive biomaterials for in situ scaffold-based cartilage regeneration. We provide a thorough review of peptides evaluated for cartilage regeneration while distinguishing between peptides reported to induce chondrogenesis independently, and peptides reported to act in synergy with other growth factors to induce cartilage regeneration. Additionally, we highlight that most peptide studies have been in vitro, and appropriate controls are not always present. A few rigorously-performed in vitro studies have proceeded to in vivo studies, but the peptides in those in vivo studies were mainly introduced via systemic, subcutaneous, or intraarticular injections, with a paucity of studies employing in situ defects with appropriate controls. Clinical translation of peptides will require the evaluation of these peptides in well-controlled in vivo cartilage defect studies. In the decade ahead, we may be poised to leverage peptides to design devices that are safe, reproducible, cost-efficient, and scalable biomaterials, which are themselves chondroinductive to achieve true hyaline cartilage regeneration without the need for growth factors and other small molecules.
Collapse
Affiliation(s)
- Boushra Ajeeb
- University of Oklahoma, 6187, Biomedical Engineering, Norman, Oklahoma, United States;
| | - Handan Acar
- University of Oklahoma, 6187, Biomedical Engineering, Norman, Oklahoma, United States;
| | | |
Collapse
|
12
|
Yan F, Gunay G, Valerio TI, Wang C, Wilson JA, Haddad MS, Watson M, Connell MO, Davidson N, Fung KM, Acar H, Tang Q. Characterization and quantification of necrotic tissues and morphology in multicellular ovarian cancer tumor spheroids using optical coherence tomography. Biomed Opt Express 2021; 12:3352-3371. [PMID: 34221665 PMCID: PMC8221959 DOI: 10.1364/boe.425512] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 05/03/2021] [Accepted: 05/07/2021] [Indexed: 05/02/2023]
Abstract
The three-dimensional (3D) tumor spheroid model is a critical tool for high-throughput ovarian cancer research and anticancer drug development in vitro. However, the 3D structure prevents high-resolution imaging of the inner side of the spheroids. We aim to visualize and characterize 3D morphological and physiological information of the contact multicellular ovarian tumor spheroids growing over time. We intend to further evaluate the distinctive evolutions of the tumor spheroid and necrotic tissue volumes in different cell numbers and determine the most appropriate mathematical model for fitting the growth of tumor spheroids and necrotic tissues. A label-free and noninvasive swept-source optical coherence tomography (SS-OCT) imaging platform was applied to obtain two-dimensional (2D) and 3D morphologies of ovarian tumor spheroids over 18 days. Ovarian tumor spheroids of two different initial cell numbers (5,000- and 50,000- cells) were cultured and imaged (each day) over the time of growth in 18 days. Four mathematical models (Exponential-Linear, Gompertz, logistic, and Boltzmann) were employed to describe the growth kinetics of the tumor spheroids volume and necrotic tissues. Ovarian tumor spheroids have different growth curves with different initial cell numbers and their growths contain different stages with various growth rates over 18 days. The volumes of 50,000-cells spheroids and the corresponding necrotic tissues are larger than that of the 5,000-cells spheroids. The formation of necrotic tissue in 5,000-cells numbers is slower than that in the 50,000-cells ones. Moreover, the Boltzmann model exhibits the best fitting performance for the growth of tumor spheroids and necrotic tissues. Optical coherence tomography (OCT) can serve as a promising imaging modality to visualize and characterize morphological and physiological features of multicellular ovarian tumor spheroids. The Boltzmann model integrating with 3D OCT data of ovarian tumor spheroids provides great potential for high-throughput cancer research in vitro and aiding in drug development.
Collapse
Affiliation(s)
- Feng Yan
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
- Equal contribution
| | - Gokhan Gunay
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
- Equal contribution
| | - Trisha I Valerio
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
- Equal contribution
| | - Chen Wang
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
| | - Jayla A Wilson
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
| | - Majood S Haddad
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
| | - Maegan Watson
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
| | - Michael O Connell
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
| | - Noah Davidson
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
| | - Kar-Ming Fung
- Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
- Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
- Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
| | - Qinggong Tang
- Stephenson School of Biomedical Engineering, University of Oklahoma, OK 73019, USA
- Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
| |
Collapse
|
13
|
Bensen RC, Gunay G, Finneran MC, Jhingan I, Acar H, Burgett AWG. Small Molecule Targeting of Oxysterol-Binding Protein (OSBP)-Related Protein 4 and OSBP Inhibits Ovarian Cancer Cell Proliferation in Monolayer and Spheroid Cell Models. ACS Pharmacol Transl Sci 2021; 4:744-756. [PMID: 33860198 DOI: 10.1021/acsptsci.0c00207] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Indexed: 12/17/2022]
Abstract
The development of precision drugs for the selective treatment of ovarian cancer will require targeting proliferative factors selectively expressed in ovarian tumors or targeting unique physiological microenvironments specific for ovarian tumors. Here, we report that oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is a potential druggable precision target in ovarian cancer cells. ORP4 has limited expression in normal tissues and was recently recognized to be a cancer-specific driver of cellular proliferation, including in patient-isolated leukemias. We demonstrate that ORP4 is strongly expressed in a panel of ovarian cancer cell lines. The antiproliferative natural product compound OSW-1 targets ORP4 and OSBP. Our results demonstrate that the OSW-1 compound has high antiproliferative potency in both monolayer and three-dimensional ovarian cancer spheroid models, especially compared to the standard-of-care agents cisplatin and paclitaxel. OSW-1 compound treatment induces a loss of ORP4 expression after 48 h, which is coincident with the cytotoxic effects of OSW-1. The absence of extracellular lipids markedly potentiated the cytotoxicity of OSW-1, which was reversed by addition of extracellular free cholesterol. OSBP, but not ORP4, is reported to transport cholesterol and other lipids between organelles. Our results indicate that the targeting of ORP4 is responsible for the antiproliferative activity of the OSW-1 compound, but that in the absence of exogenously supplied cholesterol, which might be similar to the in vivo ovarian cancer microenvironment, possible OSW-1 targeting of OSBP further potentiates the anticancer activity of the compound. Overall, ORP4 and potentially OSBP are revealed as potential druggable targets for the development of novel treatments for ovarian cancer.
Collapse
Affiliation(s)
- Ryan C Bensen
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Gokhan Gunay
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Matthew C Finneran
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Isha Jhingan
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.,Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States
| | - Anthony W G Burgett
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.,Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, United States.,Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States
| |
Collapse
|
14
|
Richter JG, Chehab G, Tomczak M, Schwartz C, Ricken E, Acar H, Gappa H, Schneider M, Velasco C, Consortium TP. AB1189 PICASO - THE PLATFORM FOR IMPROVED PERSONAL AND COORDINATED CARE OF CHRONICALLY ILL – SIX MONTHS RESULTS FROM A PROOF-OF-CONCEPT STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Cross-sectoral coordination of treatment plans and efficient management of patients with chronic diseases and co-morbidities are of great importance. In rheumatoid arthritis (RA) it is essential to orchestrate information available for a patient at various locations, to allow (cost) efficient data use, to optimize management processes and to avoid redundant diagnostics. The information and communication platform developed in the Horizon2020 funded PICASO project (www.picaso-project.eu) supports the management of patients and their data along the continuum of care, consisting of hospitals, outpatient departments, practices, other health service providers via remote health monitoring. The platform might empower patients to improve their self-management of their illnesses.Objectives:What technological expertise and resources do RA patients and physicians have, who are willing to participate in a proof-of-concept study using a modern ICT platform? What is the user satisfaction? What are platform`s clinical implications?Methods:PICASO pursued a user-centered design approach. Platform`s user requirements were determined through workshops and interviews with physicians from various disciplines, patients and other stakeholders in the health care system (e.g. data protection officers). The development was accompanied by so-called “expert walkthroughs” to ensure a user-friendly design. An evaluation concept assessing the usability of the applications, user satisfaction and clinical relevance of the platform was part of the 6-month proof-of-concept study with RA patients and their physicians (rheumatologists and family doctors). A positive ethics vote was obtained.Results:111 user requirements were identified and used to develop the platform. Conformity with the GDPR as well as national regulations were precisely adhered to. All developments are based on the new ‘Fast Healthcare Interoperability Resources’ standard enabling data exchange with other software systems in the healthcare sector. This offers many advantages, e.g. a semantic model for describing the smallest units in the health care system (e.g. medication intake times, diagnostic procedures). Thus information can be linked and made available across sectors. Data can remain with the data owner and role-specific data access is ensured.30 RA patients (80% female) participated, mean age was 58.6±10.8 years, disease duration 12.6±8.5 years, DAS28 2.6±0.9, average number of comorbidities 3.0±1.6. Patients’ IT-experience was heterogeneous. After 6 months evaluations showed a good platform acceptance with an overall rating of 2.3±1.1 (n=27, Likert scale (LS) 1-6) and evaluation of ‘ease of use’ at 2.3±1.2 (n=27, LS 1-6). Usability tests showed that for patients the presentation of (1) tasks to be performed for the management of their disease, (2) results from their remote health monitoring, and (3) patient-reported outcome instruments in a dashboard was clear and easy to understand. Time required for documentation and daily tasks was rated as appropriate by 75.9% of the patients. No major technical problems or impairments due to RA where experienced when using the dashboard. 8 physicians (37.5 % female) participated in the evaluation; overall the platform was rated at 2.2±0.5 (LS 1-6).Conclusion:The platform offers cross-sectoral orchestration of patient data and thus innovative capabilities for modern management processes (e.g. treat-to-target, tele-monitoring). The PICASO platform is available for RA patients as well as for other chronic diseases.Acknowledgments:This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 689209.Disclosure of Interests:None declared
Collapse
|
15
|
Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. Publisher Correction: On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol 2019; 14:902. [PMID: 31358944 PMCID: PMC7875076 DOI: 10.1038/s41565-019-0538-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Hon S Leong
- Department of Urology, Mayo Clinic, Rochester, MN, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA
| | - Kimberly S Butler
- Department of Nanobiology, Sandia National Laboratories, Albuquerque, NM, USA
| | - C Jeffrey Brinker
- Center for Micro-Engineered Materials, University of New Mexico Albuquerque, Albuquerque, NM, USA
- Departments of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA
- Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM, USA
- UNM Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA
| | - May Azzawi
- Cardiovascular Research Group, School of Healthcare Science, Manchester Metropolitan University, Manchester, UK
- British Society for Nanomedicine
| | - Steve Conlan
- British Society for Nanomedicine
- Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, UK
| | - Christine Dufès
- British Society for Nanomedicine
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
| | - Andrew Owen
- British Society for Nanomedicine
- Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - Steve Rannard
- British Society for Nanomedicine
- Department of Chemistry, School of Physical Sciences, University of Liverpool, Liverpool, UK
| | - Chris Scott
- British Society for Nanomedicine
- Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK
| | - Chunying Chen
- National Center for Nanoscience and Technology of China, Beijing, China
| | - Marina A Dobrovolskaia
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
- Laboratory of Animal Sciences Program, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Serguei V Kozlov
- Laboratory of Animal Sciences Program, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Adriele Prina-Mello
- Trinity Translational Medicine Institute, Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
- Laboratory for Biological Characterisation of Advanced Materials, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
- Nanomedicine Group, Advanced Materials and Bioengineering Research (AMBER) centre, Centre for Research on Adaptive Nanostructures and Nanodevices, Trinity College Dublin, Dublin, Ireland
| | | | - Peter Wick
- Empa - Swiss Federal Laboratories for Materials Science and Technology, St Gallen, Switzerland
| | - Fanny Caputo
- University Grenoble Alpes, CEA, LETI, Grenoble, Switzerland
| | | | - Rachael M Crist
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Scott E McNeil
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Bengt Fadeel
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Lang Tran
- Institute of Occupational Medicine, Edinburgh, UK
| | - Steffen Foss Hansen
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Nanna B Hartmann
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lauge P W Clausen
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lars M Skjolding
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Anders Baun
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Marlene Ågerstrand
- Department of Environmental Science and Analytical Chemistry (ACES), Stockholm University, Stockholm, Sweden
| | - Zhen Gu
- Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | | | - Clare Hoskins
- Institute of Science and Technology in Medicine, Keele University, Keele, UK
| | - Leaf Huang
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Wantong Song
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
| | - Huiliang Cao
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
- Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Jena, Germany
| | - Xuanyong Liu
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
| | - Klaus D Jandt
- Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Jena, Germany
| | - Wen Jiang
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Betty Y S Kim
- Department of Neurosurgery, The University of Texas MD Anderson Cancer, Houston, TX, USA
| | - Korin E Wheeler
- Department of Chemistry and Biochemistry, Santa Clara University, Santa Clara, CA, USA
| | - Andrew J Chetwynd
- School of Geography Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - Iseult Lynch
- School of Geography Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - Seyed Moein Moghimi
- School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - André Nel
- Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Tian Xia
- Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Paul S Weiss
- Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Materials Science and Engineering, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Bruno Sarmento
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
| | - José das Neves
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
| | - Hélder A Santos
- Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Luis Santos
- Dosage Form Design and Development, MedImmune, LLC, Gaithersburg, MD, USA
| | - Samir Mitragotri
- Wyss Institute of Biologically Inspired Engineering, Harvard University, Cambridge, MA, USA
| | - Steve Little
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA
| | - Dan Peer
- George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Mansoor M Amiji
- School of Pharmacy, Northeastern University, Boston, MA, USA
| | - Maria José Alonso
- CIMUS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Alke Petri-Fink
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Sandor Balog
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Aaron Lee
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Barbara Drasler
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | | | - Stefan Wilhelm
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - Roger G Harrison
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
- School of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA
| | - Chuanbin Mao
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA
- School of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, China
| | - Priyabrata Mukherjee
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Rajagopal Ramesh
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Lacey R McNally
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Department of Bioengineering, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Sara Busatto
- Department of Transplantation Medicine, Mayo Clinic, Jacksonville, FL, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- CSGI, Research Center for Colloids and Nanoscience, Florence, Italy
| | - Joy Wolfram
- Department of Transplantation Medicine, Mayo Clinic, Jacksonville, FL, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Paolo Bergese
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- CSGI, Research Center for Colloids and Nanoscience, Florence, Italy
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
- Department of Medicine, Weill Cornell Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Ronnie H Fang
- Department of NanoEngineering, Chemical Engineering Program, University of California, San Diego, La Jolla, CA, USA
| | - Liangfang Zhang
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Jie Zheng
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Chuanqi Peng
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Bujie Du
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Mengxiao Yu
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Danielle M Charron
- Institute of Biomaterials and Biomedical Engineering, University of Toronto Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Gang Zheng
- Department of Medical Biophysics, University of Toronto Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | | |
Collapse
|
16
|
Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, Neves JD, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. Publisher Correction: On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol 2019; 14:811. [PMID: 31289407 DOI: 10.1038/s41565-019-0523-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Hon S Leong
- Department of Urology, Mayo Clinic, Rochester, MN, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA
| | - Kimberly S Butler
- Department of Nanobiology, Sandia National Laboratories, Albuquerque, NM, USA
| | - C Jeffrey Brinker
- Center for Micro-Engineered Materials, University of New Mexico Albuquerque, Albuquerque, NM, USA
- Departments of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA
- Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM, USA
- UNM Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA
| | - May Azzawi
- Cardiovascular Research Group, School of Healthcare Science, Manchester Metropolitan University, Manchester, UK
- British Society for Nanomedicine, Liverpool, UK
| | - Steve Conlan
- British Society for Nanomedicine, Liverpool, UK
- Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, UK
| | - Christine Dufès
- British Society for Nanomedicine, Liverpool, UK
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
| | - Andrew Owen
- British Society for Nanomedicine, Liverpool, UK
- Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - Steve Rannard
- British Society for Nanomedicine, Liverpool, UK
- Department of Chemistry, School of Physical Sciences, University of Liverpool, Liverpool, UK
| | - Chris Scott
- British Society for Nanomedicine, Liverpool, UK
- Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK
| | - Chunying Chen
- National Center for Nanoscience and Technology of China, Beijing, China
| | - Marina A Dobrovolskaia
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
- Laboratory of Animal Sciences Program, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Serguei V Kozlov
- Laboratory of Animal Sciences Program, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Adriele Prina-Mello
- Trinity Translational Medicine Institute, Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
- Laboratory for Biological Characterisation of Advanced Materials, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
- Nanomedicine Group, Advanced Materials and Bioengineering Research (AMBER) centre, Centre for Research on Adaptive Nanostructures and Nanodevices, Trinity College Dublin, Dublin, Ireland
| | | | - Peter Wick
- Empa -Swiss Federal Laboratories for Materials Science and Technology, St Gallen, Switzerland
| | - Fanny Caputo
- University Grenoble Alpes, CEA, LETI, Grenoble, Switzerland
| | | | - Rachael M Crist
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Scott E McNeil
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Bengt Fadeel
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Lang Tran
- Institute of Occupational Medicine, Edinburgh, UK
| | - Steffen Foss Hansen
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Nanna B Hartmann
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lauge P W Clausen
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lars M Skjolding
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Anders Baun
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Marlene Ågerstrand
- Department of Environmental Science and Analytical Chemistry (ACES), Stockholm University, Stockholm, Sweden
| | - Zhen Gu
- Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | | | - Clare Hoskins
- Institute of Science and Technology in Medicine, Keele University, Keele, UK
| | - Leaf Huang
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Wantong Song
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
| | - Huiliang Cao
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
- Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Jena, Germany
| | - Xuanyong Liu
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
| | - Klaus D Jandt
- Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Jena, Germany
| | - Wen Jiang
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Betty Y S Kim
- Department of Neurosurgery, The University of Texas MD Anderson Cancer, Houston, TX, USA
| | - Korin E Wheeler
- Department of Chemistry and Biochemistry, Santa Clara University, Santa Clara, CA, USA
| | - Andrew J Chetwynd
- School of Geography Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - Iseult Lynch
- School of Geography Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - Sayed Moein Moghimi
- School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - André Nel
- Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Tian Xia
- Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Paul S Weiss
- Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Materials Science and Engineering, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Bruno Sarmento
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
| | - José das Neves
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
| | - Hélder A Santos
- Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Luis Santos
- Dosage Form Design and Development, MedImmune, LLC, Gaithersburg, MD, USA
| | - Samir Mitragotri
- Wyss Institute of Biologically Inspired Engineering, Harvard University, Cambridge, MA, USA
| | - Steve Little
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA
| | - Dan Peer
- George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Mansoor M Amiji
- School of Pharmacy, Northeastern University, Boston, MA, USA
| | - Maria José Alonso
- CIMUS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Alke Petri-Fink
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Sandor Balog
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Aaron Lee
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Barbara Drasler
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | | | - Stefan Wilhelm
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - Roger G Harrison
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
- School of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA
| | - Chuanbin Mao
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA
- School of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, China
| | - Priyabrata Mukherjee
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Rajagopal Ramesh
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Lacey R McNally
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Department of Bioengineering, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Sara Busatto
- Department of Transplantation Medicine, Mayo Clinic, Jacksonville, FL, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- CSGI, Research Center for Colloids and Nanoscience, Florence, Italy
| | - Joy Wolfram
- Department of Transplantation Medicine, Mayo Clinic, Jacksonville, FL, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Paolo Bergese
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- CSGI, Research Center for Colloids and Nanoscience, Florence, Italy
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
- Department of Medicine, Weill Cornell Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Ronnie H Fang
- Department of NanoEngineering, Chemical Engineering Program, University of California, San Diego, La Jolla, CA, USA
| | - Liangfang Zhang
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Jie Zheng
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Chuanqi Peng
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Bujie Du
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Mengxiao Yu
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Danielle M Charron
- Institute of Biomaterials and Biomedical Engineering, University of Toronto Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Gang Zheng
- Department of Medical Biophysics, University of Toronto Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | | |
Collapse
|
17
|
Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufés C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol 2019; 14:629-635. [PMID: 31270452 PMCID: PMC6939883 DOI: 10.1038/s41565-019-0496-9] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Affiliation(s)
- Hon S Leong
- Department of Urology, Mayo Clinic, Rochester, MN, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA
| | - Kimberly S Butler
- Department of Nanobiology, Sandia National Laboratories, Albuquerque, NM, USA
| | - C Jeffrey Brinker
- Center for Micro-Engineered Materials, University of New Mexico Albuquerque, Albuquerque, NM, USA
- Departments of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA
- Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM, USA
- UNM Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA
| | - May Azzawi
- Cardiovascular Research Group, School of Healthcare Science, Manchester Metropolitan University, Manchester, UK
- British Society for Nanomedicine
| | - Steve Conlan
- British Society for Nanomedicine
- Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, UK
| | - Christine Dufés
- British Society for Nanomedicine
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
| | - Andrew Owen
- British Society for Nanomedicine
- Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - Steve Rannard
- British Society for Nanomedicine
- Department of Chemistry, School of Physical Sciences, University of Liverpool, Liverpool, UK
| | - Chris Scott
- British Society for Nanomedicine
- Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK
| | - Chunying Chen
- National Center for Nanoscience and Technology of China, Beijing, China
| | - Marina A Dobrovolskaia
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
- Laboratory of Animal Sciences Program, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Serguei V Kozlov
- Laboratory of Animal Sciences Program, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Adriele Prina-Mello
- Trinity Translational Medicine Institute, Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
- Laboratory for Biological Characterisation of Advanced Materials, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
- Nanomedicine Group, Advanced Materials and Bioengineering Research (AMBER) centre, Centre for Research on Adaptive Nanostructures and Nanodevices, Trinity College Dublin, Dublin, Ireland
| | | | - Peter Wick
- Empa - Swiss Federal Laboratories for Materials Science and Technology, St Gallen, Switzerland
| | - Fanny Caputo
- University Grenoble Alpes, CEA, LETI, Grenoble, Switzerland
| | | | - Rachael M Crist
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Scott E McNeil
- Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Bengt Fadeel
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Lang Tran
- Institute of Occupational Medicine, Edinburgh, UK
| | - Steffen Foss Hansen
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Nanna B Hartmann
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lauge P W Clausen
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lars M Skjolding
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Anders Baun
- Department of Environmental Engineering, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Marlene Ågerstrand
- Department of Environmental Science and Analytical Chemistry (ACES), Stockholm University, Stockholm, Sweden
| | - Zhen Gu
- Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | | | - Clare Hoskins
- Institute of Science and Technology in Medicine, Keele University, Keele, UK
| | - Leaf Huang
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Wantong Song
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
| | - Huiliang Cao
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
- Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Jena, Germany
| | - Xuanyong Liu
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
| | - Klaus D Jandt
- Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Jena, Germany
| | - Wen Jiang
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Betty Y S Kim
- Department of Neurosurgery, The University of Texas MD Anderson Cancer, Houston, TX, USA
| | - Korin E Wheeler
- Department of Chemistry and Biochemistry, Santa Clara University, Santa Clara, CA, USA
| | - Andrew J Chetwynd
- School of Geography Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - Iseult Lynch
- School of Geography Earth and Environmental Sciences, University of Birmingham, Birmingham, UK
| | - Seyed Moein Moghimi
- School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - André Nel
- Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Tian Xia
- Division of NanoMedicine, Department of Medicine, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Paul S Weiss
- Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Materials Science and Engineering, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA
| | - Bruno Sarmento
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
| | - José das Neves
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal
| | - Hélder A Santos
- Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Luis Santos
- Dosage Form Design and Development, MedImmune, LLC, Gaithersburg, MD, USA
| | - Samir Mitragotri
- Wyss Institute of Biologically Inspired Engineering, Harvard University, Cambridge, MA, USA
| | - Steve Little
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA
| | - Dan Peer
- George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Mansoor M Amiji
- School of Pharmacy, Northeastern University, Boston, MA, USA
| | - Maria José Alonso
- CIMUS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Alke Petri-Fink
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Sandor Balog
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Aaron Lee
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | - Barbara Drasler
- Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland
| | | | - Stefan Wilhelm
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
| | - Roger G Harrison
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA
- Stephenson Cancer Center, Oklahoma City, OK, USA
- School of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA
| | - Chuanbin Mao
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA
- School of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, China
| | - Priyabrata Mukherjee
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Rajagopal Ramesh
- Stephenson Cancer Center, Oklahoma City, OK, USA
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Lacey R McNally
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Department of Bioengineering, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Sara Busatto
- Department of Transplantation Medicine, Mayo Clinic, Jacksonville, FL, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- CSGI, Research Center for Colloids and Nanoscience, Florence, Italy
| | - Joy Wolfram
- Department of Transplantation Medicine, Mayo Clinic, Jacksonville, FL, USA
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Paolo Bergese
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- CSGI, Research Center for Colloids and Nanoscience, Florence, Italy
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
- Department of Medicine, Weill Cornell Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Ronnie H Fang
- Department of NanoEngineering, Chemical Engineering Program, University of California, San Diego, La Jolla, CA, USA
| | - Liangfang Zhang
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Jie Zheng
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Chuanqi Peng
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Bujie Du
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Mengxiao Yu
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA
| | - Danielle M Charron
- Institute of Biomaterials and Biomedical Engineering, University of Toronto Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Gang Zheng
- Department of Medical Biophysics, University of Toronto Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | | |
Collapse
|
18
|
Kerimoglu O, Pekin A, Yılmaz S, İncesu F, Nergiz S, Doğan N, Acar H, Celik C. Effect of the FSH receptor polymorphism on the age at menarche. CLIN EXP OBSTET GYN 2019. [DOI: 10.12891/ceog4404.2019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
19
|
Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev 2019; 143:68-96. [PMID: 31022434 DOI: 10.1016/j.addr.2019.04.008] [Citation(s) in RCA: 459] [Impact Index Per Article: 91.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 04/14/2019] [Accepted: 04/19/2019] [Indexed: 12/12/2022]
Abstract
Nanoparticle-based therapeutics and diagnostics are commonly referred to as nanomedicine and may significantly impact the future of healthcare. However, the clinical translation of these technologies is challenging. One of these challenges is the efficient delivery of nanoparticles to specific cell populations and subcellular targets in the body to elicit desired biological and therapeutic responses. It is critical for researchers to understand the fundamental concepts of how nanoparticles interact with biological systems to predict and control in vivo nanoparticle transport for improved clinical benefit. In this overview article, we review and discuss cellular internalization pathways, summarize the field`s understanding of how nanoparticle physicochemical properties affect cellular interactions, and explore and discuss intracellular nanoparticle trafficking and kinetics. Our overview may provide a valuable resource for researchers and may inspire new studies to expand our current understanding of nanotechnology-biology interactions at cellular and subcellular levels with the goal to improve clinical translation of nanomedicines.
Collapse
Affiliation(s)
- Nathan D Donahue
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Handan Acar
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States; Stephenson Cancer Center, Oklahoma City, Oklahoma 73104, United States.
| | - Stefan Wilhelm
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States; Stephenson Cancer Center, Oklahoma City, Oklahoma 73104, United States.
| |
Collapse
|
20
|
Genç A, Tutkun E, Güven D, Acar H. Investigation of the endometrial thickness and estrogen level in athletes and sedentaries. CLIN EXP OBSTET GYN 2019. [DOI: 10.12891/ceog4531.2019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
21
|
Ziemba C, Khavkin M, Priftis D, Acar H, Mao J, Benami M, Gottlieb M, Tirrell M, Kaufman Y, Herzberg M. Antifouling Properties of a Self-Assembling Glutamic Acid-Lysine Zwitterionic Polymer Surface Coating. Langmuir 2019; 35:1699-1713. [PMID: 29641904 DOI: 10.1021/acs.langmuir.8b00181] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
There is a need for the development of antifouling materials to resist adsorption of biomacromolecules. Here we describe the preparation of a novel zwitterionic block copolymer with the potential to prevent or delay the formation of microbial biofilms. The block copolymer comprised a zwitterionic (hydrophilic) section of alternating glutamic acid (negatively charged) and lysine (positively charged) units and a hydrophobic polystyrene section. Cryo-TEM and dynamic-light-scattering (DLS) results showed that, on average, the block copolymer self-assembled into 7-nm-diameter micelles in aqueous solutions (0 to 100 mM NaCl, pH 6). Quartz crystal microbalance with dissipation monitoring (QCM-D), atomic force microscopy (AFM), and contact angle measurements demonstrated that the block copolymer self-assembled into a brush-like monolayer on polystyrene surfaces. The brush-like monolayer produced from a 100 mg/L block copolymer solution exhibited an average distance, d, of approximately 4-8 nm between each block copolymer molecule (center to center). Once the brush-like monolayer self-assembled, it reduced EPS adsorption onto the polystyrene surface by ∼70% (mass), reduced the rate of bacterial attachment by >80%, and inhibited the development of thick biofilms. QCM-D results revealed that the EPS molecules penetrate between the chains of the brush and adsorb onto the polystyrene surface. Additionally, AFM analyses showed that the brush-like monolayer prevents the adhesion of large (> d) hydrophilic colloids onto the surface via hydration repulsion; however, molecules or colloids small enough to fit between the brush polymers (< d) were able to be adsorbed onto the surface via van der Waals interactions. Overall, we found that the penetration of extracellular organelles, as well as biopolymers through the brush, is critical for the failure of the antifouling coating, and likely could be prevented through tuning of the brush density. Stability and biofilm development testing on multiple surfaces (polypropylene, glass, and stainless steel) support practical applications of this novel block copolymer.
Collapse
Affiliation(s)
- Christopher Ziemba
- The Jacob Blaustein Institutes for Desert Research, Zuckerberg Institute for Water Research, The Albert Katz International School of Desert Studies , Ben Gurion University of the Negev , Sede Boqer Campus, Midreshet Ben-Gurion , 84990 , Israel
| | - Maria Khavkin
- The Jacob Blaustein Institutes for Desert Research, Zuckerberg Institute for Water Research, The Albert Katz International School of Desert Studies , Ben Gurion University of the Negev , Sede Boqer Campus, Midreshet Ben-Gurion , 84990 , Israel
| | - Dimitris Priftis
- Institute for Molecular Engineering , University of Chicago , Chicago , Illinois 60637 , United States
| | - Handan Acar
- Institute for Molecular Engineering , University of Chicago , Chicago , Illinois 60637 , United States
| | - Jun Mao
- Institute for Molecular Engineering , University of Chicago , Chicago , Illinois 60637 , United States
| | - Maya Benami
- The Jacob Blaustein Institutes for Desert Research, Zuckerberg Institute for Water Research, The Albert Katz International School of Desert Studies , Ben Gurion University of the Negev , Sede Boqer Campus, Midreshet Ben-Gurion , 84990 , Israel
| | - Moshe Gottlieb
- Department of Chemical Engineering , Ben Gurion University of the Negev , Beer-Sheva 84105 Israel
| | - Matthew Tirrell
- Institute for Molecular Engineering , University of Chicago , Chicago , Illinois 60637 , United States
- Materials Science Division , Argonne National Laboratory , Argonne , Illinois 60439 , United States
| | - Yair Kaufman
- The Jacob Blaustein Institutes for Desert Research, Zuckerberg Institute for Water Research, The Albert Katz International School of Desert Studies , Ben Gurion University of the Negev , Sede Boqer Campus, Midreshet Ben-Gurion , 84990 , Israel
| | - Moshe Herzberg
- The Jacob Blaustein Institutes for Desert Research, Zuckerberg Institute for Water Research, The Albert Katz International School of Desert Studies , Ben Gurion University of the Negev , Sede Boqer Campus, Midreshet Ben-Gurion , 84990 , Israel
| |
Collapse
|
22
|
Abstract
Proteins and their interactions in and out of cells must be well-orchestrated for the healthy functioning and regulation of the body. Even the slightest disharmony can cause diseases. Therapeutic peptides are short amino acid sequences (generally considered <50 amino acids) that can naturally mimic the binding interfaces between proteins and thus, influence protein-protein interactions. Because of their fidelity of binding, peptides are a promising next generation of personalized medicines to reinstate biological harmony. Peptides as a group are highly selective, relatively safe, and biocompatible. However, they are also vulnerable to many in vivo pharmacologic barriers limiting their clinical translation. Current advances in molecular, chemical, and nanoparticle engineering are helping to overcome these previously insurmountable obstacles and improve the future of peptides as active and highly selective therapeutics. In this review, we focus on self-assembled vehicles as nanoparticles to carry and protect therapeutic peptides through this journey, and deliver them to the desired tissue.
Collapse
Affiliation(s)
- Handan Acar
- Institute for Molecular Engineering, The University of Chicago, Chicago, IL 60637, USA.
| | | | | | | | | |
Collapse
|
23
|
Acar H, Samaeekia R, Schnorenberg MR, Sasmal DK, Huang J, Tirrell MV, LaBelle JL. Cathepsin-Mediated Cleavage of Peptides from Peptide Amphiphiles Leads to Enhanced Intracellular Peptide Accumulation. Bioconjug Chem 2017; 28:2316-2326. [PMID: 28771332 DOI: 10.1021/acs.bioconjchem.7b00364] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Peptides synthesized in the likeness of their native interaction domain(s) are natural choices to target protein-protein interactions (PPIs) due to their fidelity of orthostatic contact points between binding partners. Despite therapeutic promise, intracellular delivery of biofunctional peptides at concentrations necessary for efficacy remains a formidable challenge. Peptide amphiphiles (PAs) provide a facile method of intracellular delivery and stabilization of bioactive peptides. PAs consisting of biofunctional peptide headgroups linked to hydrophobic alkyl lipid-like tails prevent peptide hydrolysis and proteolysis in circulation, and PA monomers are internalized via endocytosis. However, endocytotic sequestration and steric hindrance from the lipid tail are two major mechanisms that limit PA efficacy to target intracellular PPIs. To address these problems, we have constructed a PA platform consisting of cathepsin-B cleavable PAs in which a selective p53-based inhibitory peptide is cleaved from its lipid tail within endosomes, allowing for intracellular peptide accumulation and extracellular recycling of the lipid moiety. We monitor for cleavage and follow individual PA components in real time using a Förster resonance energy transfer (FRET)-based tracking system. Using this platform, we provide a better understanding and quantification of cellular internalization, trafficking, and endosomal cleavage of PAs and of the ultimate fates of each component.
Collapse
Affiliation(s)
- Handan Acar
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States
| | - Ravand Samaeekia
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States
| | - Mathew R Schnorenberg
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States.,Medical Scientist Training Program, University of Chicago , 924 East 57th Street, Suite 104, Chicago, Illinois 60637, United States
| | - Dibyendu K Sasmal
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States
| | - Jun Huang
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States
| | - Matthew V Tirrell
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Institute for Molecular Engineering, Argonne National Laboratory , 9700 South Cass Avenue, Argonne, Illinois 60639, United States
| | - James L LaBelle
- Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States
| |
Collapse
|
24
|
Kucukmorkoc E, Kucuk N, Doyuran M, Acar H, Canoglu D, Rashad R, Caglar H. EP-1587: feasibility investigation of prone position robotic radiosurgery treatment for dorsal metastasis. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32022-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
25
|
Acar H, Srivastava S, Chung EJ, Schnorenberg MR, Barrett JC, LaBelle JL, Tirrell M. Self-assembling peptide-based building blocks in medical applications. Adv Drug Deliv Rev 2017; 110-111:65-79. [PMID: 27535485 PMCID: PMC5922461 DOI: 10.1016/j.addr.2016.08.006] [Citation(s) in RCA: 148] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 07/01/2016] [Accepted: 08/05/2016] [Indexed: 12/22/2022]
Abstract
Peptides and peptide-conjugates, comprising natural and synthetic building blocks, are an increasingly popular class of biomaterials. Self-assembled nanostructures based on peptides and peptide-conjugates offer advantages such as precise selectivity and multifunctionality that can address challenges and limitations in the clinic. In this review article, we discuss recent developments in the design and self-assembly of various nanomaterials based on peptides and peptide-conjugates for medical applications, and categorize them into two themes based on the driving forces of molecular self-assembly. First, we present the self-assembled nanostructures driven by the supramolecular interactions between the peptides, with or without the presence of conjugates. The studies where nanoassembly is driven by the interactions between the conjugates of peptide-conjugates are then presented. Particular emphasis is given to in vivo studies focusing on therapeutics, diagnostics, immune modulation and regenerative medicine. Finally, challenges and future perspectives are presented.
Collapse
Affiliation(s)
- Handan Acar
- Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA; Department of Pediatrics, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
| | - Samanvaya Srivastava
- Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA; Institute for Molecular Engineering, Argonne National Laboratory, Argonne, IL 60439, USA.
| | - Eun Ji Chung
- Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA; Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA
| | - Mathew R Schnorenberg
- Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA; Department of Pediatrics, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA; Medical Scientist Training Program, University of Chicago, Chicago, IL 60637, USA.
| | - John C Barrett
- Biophysical Sciences Graduate Program, University of Chicago, Chicago, IL 60637, USA.
| | - James L LaBelle
- Department of Pediatrics, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
| | - Matthew Tirrell
- Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA; Institute for Molecular Engineering, Argonne National Laboratory, Argonne, IL 60439, USA.
| |
Collapse
|
26
|
Codel G, Serin E, Cebe M, Mabhouti H, Pacaci P, Sanli E, Doyuran M, Kucukmorkoc E, Altinok A, Canoglu D, Kucuk N, Acar H, Caglar H. Accuracy of the small field dosimetry using Acuros XB and AAA dose calculation algorithms of eclipse treatment planning system within and beyond heterogeneous media for Trubeam 2.0 unit. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.07.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
27
|
Mabhouti H, Sanli E, Cebe M, Codel G, Pacaci P, Serin E, Doyuran M, Kucukmorkoc E, Altinok A, Canoglu D, Kucuk N, Acar H, Caglar H. The dosimetric comparison of Truebeam and Cyberknife treatment planning systems dose calculation accuracy for brain SRS treatment on Randophantom. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.07.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
28
|
Serin E, Codel G, Cebe M, Mabhouti H, Pacaci P, Sanli E, Doyuran M, Kucukmorkoc E, Altinok A, Canoglu D, Kucuk N, Acar H, Caglar H. Accuracy of the small field dosimetry using the monte carlo and sequential dose calculation algorithms of Multiplan treatment planning system within and beyond heterogeneous media for Cyberknife M6 unit. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.07.595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
29
|
Sanli E, Mabhouti H, Cebe M, Codel G, Pacaci P, Serin E, Kucuk N, Kucukmorkoc E, Doyuran M, Canoglu D, Altinok A, Acar H, Caglar Ozkok H. SU-F-SPS-10: The Dosimetric Comparison of GammaKnife and Cyberknife Treatment Plans for Brain SRS Treatment. Med Phys 2016. [DOI: 10.1118/1.4955685] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Mabhouti H, Sanli E, Cebe M, Codel G, Pacaci P, Serin E, Kucuk N, Kucukmorkoc E, Doyuran M, Canoglu D, Altinok A, Acar H, Caglar Ozkok H. SU-F-SPS-11: The Dosimetric Comparison of Truebeam 2.0 and Cyberknife M6 Treatment Plans for Brain SRS Treatment. Med Phys 2016. [DOI: 10.1118/1.4955686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
31
|
Acar H, Cebe M, Mabhouti H, Codel G, Pacaci P, Serin E, Sanli E, Kucuk N, Kucukmorkoc E, Doyuran M, Canoglu D, Altinok A, Caglar H. SU-F-T-616: Comparison of Different Techniques Using RTOG0631 Guidelines in Spine SBRT. Med Phys 2016. [DOI: 10.1118/1.4956801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
32
|
Pacaci P, Cebe M, Mabhouti H, Codel G, Serin E, Sanli E, Kucukmorkoc E, Doyuran M, Kucuk N, Canoglu D, Altinok A, Acar H, Caglar Ozkok H. SU-F-SPS-04: Dosimetric Evaluation of the Dose Calculation Accuracy of Different Algorithms for Two Different Treatment Techniques During Whole Breast Irradiation. Med Phys 2016. [DOI: 10.1118/1.4955679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Cebe M, Pacaci P, Mabhouti H, Codel G, Sanli E, Serin E, Kucuk N, Kucukmorkoc E, Doyuran M, Canoglu D, Altinok A, Acar H, Caglar Ozkok H. SU-F-SPS-05: Experimental Validation of Peripheral Dose Distribution of Electron Beams for Eclipse Electron Monte Carlo Algorithm. Med Phys 2016. [DOI: 10.1118/1.4955680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Codel G, Serin E, Pacaci P, Sanli E, Cebe M, Mabhouti H, Doyuran M, Kucukmorkoc E, Kucuk N, Altinok A, Canoglu D, Acar H, Caglar Ozkok H. SU-F-SPS-01: Accuracy of the Small Field Dosimetry Using Acuros XB and AAA Dose Calculation Algorithms of Eclipse Treatment Planning System Within and Beyond Heterogeneous Media for Trubeam 2.0 Unit. Med Phys 2016. [DOI: 10.1118/1.4955676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Serin E, Codel G, Mabhouti H, Cebe M, Sanli E, Pacaci P, Kucuk N, Kucukmorkoc E, Doyuran M, Canoglu D, Altinok A, Acar H, Caglar Ozkok H. SU-F-SPS-02: Accuracy of the Small Field Dosimetry Using the Monte Carlo and Sequential Dose Calculation Algorithms of Multiplan Treatment Planning System Within and Beyond Heterogeneous Media for Cyberknife M6 Unit. Med Phys 2016. [DOI: 10.1118/1.4955677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
36
|
Acar H, Banerjee S, Shi H, Jamshidi R, Hashemi N, Cho MW, Montazami R. Transient Biocompatible Polymeric Platforms for Long-Term Controlled Release of Therapeutic Proteins and Vaccines. Materials (Basel) 2016; 9:321. [PMID: 28546855 PMCID: PMC5441878 DOI: 10.3390/ma9050321] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 04/22/2016] [Indexed: 11/29/2022]
Abstract
Polymer-based interpenetrating networks (IPNs) with controllable and programmable degradation and release kinetics enable unique opportunities for physisorption and controlled release of therapeutic proteins or vaccines while their chemical and structural integrities are conserved. This paper presents materials, a simple preparation method, and release kinetics of a series of long-term programmable, biocompatible, and biodegradable polymer-based IPN controlled release platforms. Release kinetics of the gp41 protein was controlled over a 30-day period via tuning and altering the chemical structure of the IPN platforms. Post-release analysis confirmed structural conservation of the gp41 protein throughout the process. Cell viability assay confirmed biocompatibility and non-cytotoxicity of the IPNs.
Collapse
Affiliation(s)
- Handan Acar
- Department of Mechanical Engineering, Iowa State University, Ames, IA 50011, USA; (H.A.); (R.J.); (N.H.)
| | - Saikat Banerjee
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA; (S.B.); (H.S.); (M.W.C.)
- Center of Advanced Host Defenses Immunobiotics and Translational Medicine, Iowa State University, Ames, IA 50011, USA
| | - Heliang Shi
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA; (S.B.); (H.S.); (M.W.C.)
- Center of Advanced Host Defenses Immunobiotics and Translational Medicine, Iowa State University, Ames, IA 50011, USA
| | - Reihaneh Jamshidi
- Department of Mechanical Engineering, Iowa State University, Ames, IA 50011, USA; (H.A.); (R.J.); (N.H.)
- Center of Advanced Host Defenses Immunobiotics and Translational Medicine, Iowa State University, Ames, IA 50011, USA
| | - Nastaran Hashemi
- Department of Mechanical Engineering, Iowa State University, Ames, IA 50011, USA; (H.A.); (R.J.); (N.H.)
- Center of Advanced Host Defenses Immunobiotics and Translational Medicine, Iowa State University, Ames, IA 50011, USA
- Ames Laboratory, Department of Energy, Ames, IA 50011, USA
| | - Michael W. Cho
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA; (S.B.); (H.S.); (M.W.C.)
- Center of Advanced Host Defenses Immunobiotics and Translational Medicine, Iowa State University, Ames, IA 50011, USA
| | - Reza Montazami
- Department of Mechanical Engineering, Iowa State University, Ames, IA 50011, USA; (H.A.); (R.J.); (N.H.)
- Center of Advanced Host Defenses Immunobiotics and Translational Medicine, Iowa State University, Ames, IA 50011, USA
- Ames Laboratory, Department of Energy, Ames, IA 50011, USA
| |
Collapse
|
37
|
Altinok A, Doyuran M, Caglar M, Canoglu D, Kucukmorkoc E, Acar H, Kucuk N, Caglar H. EP-1190: Boost volume assessment in breast cancer: preop tumor volume vs clips used in oncoplastic surgery. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32440-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Acar H, Yavas G, Yavas C. The impact of dose calculatıon algorıthms for perıpheral dose dıstrıbutıons of enhanced dynamıc and physıcal wedges. INT J RADIAT RES 2016. [DOI: 10.18869/acadpub.ijrr.14.1.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
39
|
Cebe M, Acar H, Kucuk N, Kucukmorkoc E, Doyuran M, Caglar M, Altinok A, Yilidir G, Mabhouti H, Caglar H. SU-E-T-726: The Analysis of Different Percentage Depth Dose Curves Used for Commissioning in Eclipse. Med Phys 2015. [DOI: 10.1118/1.4925090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
Mabhouti H, Acar H, Kucuk N, Kucukmorkoc E, Doyuran M, Caglar M, Altinok A, Cebe M, Yilidir G, Caglar H. SU-E-T-725: The Analysis of Different Diagonal Profiles Used for Commissioning in Eclipse. Med Phys 2015. [DOI: 10.1118/1.4925089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
41
|
Yilidir G, Acar H, Kucuk N, Kucukmorkoc E, Doyuran M, Caglar M, Altinok A, Cebe M, Mabhouti H, Caglar H. SU-E-T-731: The Effect of Thermoplatic Mask to the Surface Dose in Sterotactic Brain Treatments with Flattening Filter Free Beams with EBT3 Gafchromic Film and OSL Dosimeter. Med Phys 2015. [DOI: 10.1118/1.4925095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Kucukmorkoc E, Doyuran M, Caglar M, Kucuk N, Acar H, Altinok A, Caglar H. EP-1414: The effect of depth and control point number for MLC transmission and dosimetric leaf gap. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41406-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Acar H, Ozbay I. PO-1033: Dosimetric comparison of dose distributions in episcleral plaque brachytherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41025-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Caglar H, Kucukmorkoc E, Kucuk N, Altinok A, Acar H, Doyuran M. EP-1335: Deformable MRI fusion for intracranial SRS: Can we trust? Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41327-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Altinok A, Acar H, Rizazade R, Kucuk N, Kucukmorkoc E, Doyuran M, Mabhouti H, Caglar H. EP-1253: Evaluation of interfractional bladder doses for two different patient positioning methods in prostate cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41245-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Demirci O, Yavuz T, Arisoy R, Pekin O, Acar H, Aydin H, Cetinkaya A, Karaman A, Erdoğdu E, Kumru P. AGENESIS OF THE DUCTUS VENOSUS--A CASE WITH NOONAN SYNDROME. Genet Couns 2015; 26:373-376. [PMID: 26625673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
47
|
Caglar HB, Altinok AY, Kucukmorkoc E, Acar H, Kucuk N. O2.06 * USE OF MRI FUSION FOR CT BASED INTRACRANIAL STEREOTACTIC RADIOSURGERY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Acar H, altinok A, kucukmorkoc E, kucuk N, caglar H. SU-E-T-548: How To Decrease Spine Dose In Patients Who Underwent Sterotactic Spine Radiosurgery? Med Phys 2014. [DOI: 10.1118/1.4888883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
49
|
Chehab G, Sander O, Richter J, Acar H, Vordenbäumen S, Brinks R, Schneider M, Fischer-Betz R. Validation and evaluation of the German Brief Index of Lupus Damage (BILD)--a self-reported instrument to record damage in systemic lupus erythematosus. Lupus 2014; 22:1050-5. [PMID: 23963433 DOI: 10.1177/0961203313500369] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Damage is a very important predictor for outcome in systemic lupus erythematosus (SLE) and should be routinely documented. Patient-reported assessments for damage are rare and neither the Lupus Damage Index Questionnaire (LDIQ) nor the Brief Index of Lupus Damage (BILD) is validated in German language. Our aim was to validate the BILD in German language and evaluate its use as a patient-administered instrument. METHOD We translated and adapted the BILD questionnaire to use it as a self-administered questionnaire for German-speaking SLE patients. It was applied to SLE outpatients at an academic centre and compared to the SLICC/SDI and other lupus outcome parameters. RESULTS The German BILD showed as strong a correlation with the SLICC/SDI as the original version of the BILD and a superior correlation compared to the LDIQ. It scored significantly higher with an increase of age, disease duration or disease activity, with a lower functional status or overall health and a higher probability of receiving an incapacity pension. CONCLUSION The German version of the BILD shows a comparable validity to the original BILD with even higher correlation to physician-reported damage even when used as a self-administered questionnaire. Hence it represents a promising instrument to survey damage in clinical routine as well as in clinical and epidemiological studies.
Collapse
Affiliation(s)
- G Chehab
- Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Ucar VB, Nami B, Acar H, Kilinç M. Is methylenetetrahydrofolate reductase (MTHFR) gene A1298C polymorphism related with varicocele risk? Andrologia 2014; 47:42-6. [PMID: 24456105 DOI: 10.1111/and.12229] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2013] [Indexed: 12/17/2022] Open
Abstract
Varicocele is one of the main reasons for male infertility the exact aetiology of which remains unclear. Methylenetetrahydrofolate reductase (MTHFR) is important for DNA synthesis and methylation, which has a key role during spermatogenesis. Numerous literature suggests that the MTHFR polymorphism may be genetic risk factors for male infertility. In this study, we evaluated C677T and A1298C MTHFR gene polymorphism frequency in patients with varicocele and normal men. A total of 107 varicocele patients and 109 fertile healthy individuals were included. Genotyping of the MTHFR gene in C677T and A1298C base pairs carried out by using real-time PCR technique and afterwards, the statistical analysis accomplished. There is a statistical difference for the frequency of 1298AA genotype in patients with varicocele compared with normal controls (P = 0.0051, OR = 2.2750). Instead, subsequently, 1298/A allel frequency in patient group was significantly higher in comparison with control group (P = 0.0174). According to our results, 1298AA genotype in MTHFR gene raises the risk of varicocele approximately 2.3 times more compared with men carrying other genotypes. The results show that genetic factors have an important role in the molecular basis of varicocele.
Collapse
Affiliation(s)
- V B Ucar
- Department of Medical Genetics, Selçuk University Medical School, Konya, Turkey
| | | | | | | |
Collapse
|